Key Takeaways SENS shares gain 2.1% after securing European CE Mark approval for the Eversense 365 CGM.Senseonics gains a one-year implantable CGM in Europe, expanding its addressable market beyond the U.S.SENS holds full commercialization rights and integration potential, supporting revenue visibility.Senseonics Holdings, Inc. (SENS) recently scored a meaningful regulatory win in Europe, receiving CE Mark approval for its Eversense 365 continuous glucose monitoring (CGM) system.The approval builds on the U ...